Mahkam Zanganeh - Mar 26, 2024 Form 4 Insider Report for Summit Therapeutics Inc. (SMMT)

Signature
/s/ Mahkam Zanganeh
Stock symbol
SMMT
Transactions as of
Mar 26, 2024
Transactions value $
$411,094
Form type
4
Date filed
3/27/2024, 08:28 PM
Previous filing
Dec 13, 2023
Next filing
Jun 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SMMT Common Stock Purchase $96.7K +26K +5.25% $3.72 521K Mar 27, 2024 Direct F1
transaction SMMT Common Stock Purchase $128K +34.3K +0.14% $3.72 24.9M Mar 27, 2024 By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee F2, F3
transaction SMMT Common Stock Purchase $113K +30K $3.75 30K Mar 26, 2024 Immediate family member F3, F4
transaction SMMT Common Stock Purchase $74.2K +20K +66.67% $3.71 50K Mar 27, 2024 Immediate family member F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.69 to $3.72 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.78 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.68 to $3.75 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.